Genetic variants in 2q31 and 5p15 are associated with aggressive benign prostatic hyperplasia in a Chinese population

Prostate

Volumn 73, Issue 11, 2013, Pages 1182-1190

  Qi, Jun ^a   Tian, Lu ^b   Chen, Zhuo ^b   Wang, Li ^b   Tao, Sha ^b   Gu, Xin ^a   Na, Rong ^b   Jiao, Yang ^a   Kang, Jian ^a   Zheng, Siqun ^b   Xu, Jianfeng ^b,c   Sun, Jielin ^b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c FUDAN UNIVERSITY   (China)

Author keywords

aggressive; association; BPH; Chinese; IRX4

Indexed keywords

IRX 4 PROTEIN; ITGA 6 PROTEIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN; RFX 6 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; CHINESE; CONTROLLED STUDY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATE VOLUME; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CHROMOSOMES, HUMAN, PAIR 2; CHROMOSOMES, HUMAN, PAIR 5; GENETIC ASSOCIATION STUDIES; GENETIC VARIATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; POLYMORPHISM, SINGLE NUCLEOTIDE; POPULATION SURVEILLANCE; PROSTATIC HYPERPLASIA;

EID: 84879389946     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22666     Document Type: Article

References (27)

1. Ziada A, Rosenblum M, Crawford ED,. Benign prostatic hyperplasia: An overview. Urology 1999; 53 (3 Suppl 3a): 1-6.
2. Hoke GP, McWilliams GW,. Epidemiology of benign prostatic hyperplasia and comorbidities in racial and ethnic minority populations. Am J Med 2008; 121 (8 Suppl 2): S3-S10.
3. Partin AW, Page WF, Lee BR, Sanda MG, Miller RN, Walsh PC,. Concordance rates for benign prostatic disease among twins suggest hereditary influence. Urology 1994; 44 (5): 646-650.
4. Mononen N, Ikonen T, Autio V, Rokman A, Matikainen MP, Tammela TL, Kallioniemi OP, Koivisto PA, Schleutker J,. Androgen receptor CAG polymorphism and prostate cancer risk. Hum Genet 2002; 111 (2): 166-171.
5. Kristal AR, Price DK, Till C, Schenk JM, Neuhouser ML, Ockers S, Lin DW, Thompson IM, Figg WD,. Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: Results from the Prostate Cancer Prevention Trial. Prostate 2010; 70 (6): 584-590.
6. Salam MT, Ursin G, Skinner EC, Dessissa T, Reichardt JK,. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer. Urol Oncol 2005; 23 (4): 246-253.
7. Roberts RO, Bergstralh EJ, Farmer SA, Jacobson DJ, McGree ME, Hebbring SJ, Cunningham JM, Anderson SA, Thibodeau SN, Lieber MM, Jacobsen SJ,. Polymorphisms in the 5alpha reductase type 2 gene and urologic measures of BPH. Prostate 2005; 62 (4): 380-387.
8. Stadler ZK, Gallagher DJ, Thom P, Offit K,. Genome-wide association studies of cancer: Principles and potential utility. Oncology (Williston Park) 2010; 24 (7): 629-637.
9. Kote-Jarai Z, Olama AA, Giles GG, Severi G, Schleutker J, Weischer M, Campa D, Riboli E, Key T, Gronberg H, Hunter DJ, Kraft P, Thun MJ, Ingles S, Chanock S, Albanes D, Hayes RB, Neal DE, Hamdy FC, Donovan JL, Pharoah P, Schumacher F, Henderson BE, Stanford JL, Ostrander EA, Sorensen KD, Dork T, Andriole G, Dickinson JL, Cybulski C, Lubinski J, Spurdle A, Clements JA, Chambers S, Aitken J, Gardiner RA, Thibodeau SN, Schaid D, John EM, Maier C, Vogel W, Cooney KA, Park JY, Cannon-Albright L, Brenner H, Habuchi T, Zhang HW, Lu YJ, Kaneva R, Muir K, Benlloch S, Leongamornlert DA, Saunders EJ, Tymrakiewicz M, Mahmud N, Guy M, O'Brien LT, Wilkinson RA, Hall AL, Sawyer EJ, Dadaev T, Morrison J, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Cooper CS, Lophatonanon A, Southey MC, Hopper JL, English DR, Wahlfors T, Tammela TL, Klarskov P, Nordestgaard BG, Roder MA, Tybjaerg-Hansen A, Bojesen SE, Travis R, Canzian F, Kaaks R, Wiklund F, Aly M, Lindstrom S, Diver WR, Gapstur S, Stern MC, Corral R, Virtamo J, Cox A, Haiman CA, Le Marchand L, Fitzgerald L, Kolb S, Kwon EM, Karyadi DM, Orntoft TF, Borre M, Meyer A, Serth J, Yeager M, Berndt SI, Marthick JR, Patterson B, Wokolorczyk D, Batra J, Lose F, McDonnell SK, Joshi AD, Shahabi A, Rinckleb AE, Ray A, Sellers TA, Lin HY, Stephenson RA, Farnham J, Muller H, Rothenbacher D, Tsuchiya N, Narita S, Cao GW, Slavov C, Mitev V, Easton DF, Eeles RA,. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet 2011; 43 (8): 785-791.
10. Schumacher FR, Berndt SI, Siddiq A, Jacobs KB, Wang Z, Lindstrom S, Stevens VL, Chen C, Mondul AM, Travis RC, Stram DO, Eeles RA, Easton DF, Giles G, Hopper JL, Neal DE, Hamdy FC, Donovan JL, Muir K, Al Olama AA, Kote-Jarai Z, Guy M, Severi G, Gronberg H, Isaacs WB, Karlsson R, Wiklund F, Xu J, Allen NE, Andriole GL, Barricarte A, Boeing H, Bueno-de-Mesquita HB, Crawford ED, Diver WR, Gonzalez CA, Gaziano JM, Giovannucci EL, Johansson M, Le Marchand L, Ma J, Sieri S, Stattin P, Stampfer MJ, Tjonneland A, Vineis P, Virtamo J, Vogel U, Weinstein SJ, Yeager M, Thun MJ, Kolonel LN, Henderson BE, Albanes D, Hayes RB, Feigelson HS, Riboli E, Hunter DJ, Chanock SJ, Haiman CA, Kraft P,. Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet 2011; 20 (19): 3867-3875.
11. Haiman CA, Chen GK, Blot WJ, Strom SS, Berndt SI, Kittles RA, Rybicki BA, Isaacs WB, Ingles SA, Stanford JL, Diver WR, Witte JS, Hsing AW, Nemesure B, Rebbeck TR, Cooney KA, Xu J, Kibel AS, Hu JJ, John EM, Gueye SM, Watya S, Signorello LB, Hayes RB, Wang Z, Yeboah E, Tettey Y, Cai Q, Kolb S, Ostrander EA, Zeigler-Johnson C, Yamamura Y, Neslund-Dudas C, Haslag-Minoff J, Wu W, Thomas V, Allen GO, Murphy A, Chang BL, Zheng SL, Leske MC, Wu SY, Ray AM, Hennis AJ, Thun MJ, Carpten J, Casey G, Carter EN, Duarte ER, Xia LY, Sheng X, Wan P, Pooler LC, Cheng I, Monroe KR, Schumacher F, Le Marchand L, Kolonel LN, Chanock SJ, Van Den Berg D, Stram DO, Henderson BE,. Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet 2011; 43 (6): 570-573.
12. Alcaraz A, Hammerer P, Tubaro A, Schroder FH, Castro R,. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Eur Urol 2009; 55 (4): 864-873.
13. Carson C III, Rittmaster R,. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 2003; 61 (4 Suppl 1): 2-7.
14. Tindall DJ, Rittmaster RS,. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. J Urol 2008; 179 (4): 1235-1242.
15. Canby-Hagino E, Hernandez J, Brand TC, Thompson I,. Looking back at PCPT: Looking forward to new paradigms in prostate cancer screening and prevention. Eur Urol 2007; 51 (1): 27-33.
16. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS,. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362 (13): 1192-1202.
17. Di Silverio F, Gentile V, De Matteis A, Mariotti G, Giuseppe V, Luigi PA, Sciarra A,. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: A retrospective analysis. Eur Urol 2003; 43 (2): 164-175.
18. MacLennan GT, Eisenberg R, Fleshman RL, Taylor JM, Fu P, Resnick MI, Gupta S,. The influence of chronic inflammation in prostatic carcinogenesis: A 5-year followup study. J Urol 2006; 176 (3): 1012-1016.
19. Liu F, Hsing AW, Wang X, Shao Q, Qi J, Ye Y, Wang Z, Chen H, Gao X, Wang G, Chu LW, Ding Q, OuYang J, Huang Y, Chen Y, Gao YT, Zhang ZF, Rao J, Shi R, Wu Q, Wang M, Zhang Z, Zhang Y, Jiang H, Zheng J, Hu Y, Guo L, Lin X, Tao S, Jin G, Sun J, Lu D, Zheng SL, Sun Y, Mo Z, Xu J,. Systematic confirmation study of reported prostate cancer risk-associated single nucleotide polymorphisms in Chinese men. Cancer Sci 2011; 102 (10): 1916-1920.
20. Wang M, Liu F, Hsing AW, Wang X, Shao Q, Qi J, Ye Y, Wang Z, Chen H, Gao X, Wang G, Chu LW, Ding Q, OuYang J, Huang Y, Chen Y, Gao YT, Zhang ZF, Rao J, Shi R, Wu Q, Zhang Y, Jiang H, Zheng J, Hu Y, Guo L, Lin X, Tao S, Jin G, Sun J, Lu D, Zheng SL, Sun Y, Mo Z, Yin C, Zhang Z, Xu J,. Replication and cumulative effects of GWAS-identified genetic variations for prostate cancer in Asians: A case-control study in the ChinaPCa consortium. Carcinogenesis 2012; 33 (2): 356-360.
21. Ma Z, Hu Q, Chen Z, Tao S, Macnamara L, Kim ST, Tian L, Xu K, Ding Q, Zheng SL, Sun J, Xia G, Xu J,. Systematic evaluation of bladder cancer risk-associated single-nucleotide polymorphisms in a Chinese population. Mol Carcinog 2012 [Epud ahead of print].
22. Eeles RA, Kote-Jarai Z, Al Olama AA, Giles GG, Guy M, Severi G, Muir K, Hopper JL, Henderson BE, Haiman CA, Schleutker J, Hamdy FC, Neal DE, Donovan JL, Stanford JL, Ostrander EA, Ingles SA, John EM, Thibodeau SN, Schaid D, Park JY, Spurdle A, Clements J, Dickinson JL, Maier C, Vogel W, Dork T, Rebbeck TR, Cooney KA, Cannon-Albright L, Chappuis PO, Hutter P, Zeegers M, Kaneva R, Zhang HW, Lu YJ, Foulkes WD, English DR, Leongamornlert DA, Tymrakiewicz M, Morrison J, Ardern-Jones AT, Hall AL, O'Brien LT, Wilkinson RA, Saunders EJ, Page EC, Sawyer EJ, Edwards SM, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Cooper CS, Southey MC, Lophatananon A, Liu JF, Kolonel LN, Le Marchand L, Wahlfors T, Tammela TL, Auvinen A, Lewis SJ, Cox A, FitzGerald LM, Koopmeiners JS, Karyadi DM, Kwon EM, Stern MC, Corral R, Joshi AD, Shahabi A, McDonnell SK, Sellers TA, Pow-Sang J, Chambers S, Aitken J, Gardiner RA, Batra J, Kedda MA, Lose F, Polanowski A, Patterson B, Serth J, Meyer A, Luedeke M, Stefflova K, Ray AM, Lange EM, Farnham J, Khan H, Slavov C, Mitkova A, Cao G, Easton DF,. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet 2009; 41 (10): 1116-1121.
23. Kumar CC,. Signaling by integrin receptors. Oncogene 1998; 17 (11 Reviews): 1365-1373.
24. Takata R, Akamatsu S, Kubo M, Takahashi A, Hosono N, Kawaguchi T, Tsunoda T, Inazawa J, Kamatani N, Ogawa O, Fujioka T, Nakamura Y, Nakagawa H,. Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nat Genet 2010; 42 (9): 751-754.
25. Wellendorph P, Brauner-Osborne H,. Molecular cloning, expression, and sequence analysis of GPRC6A, a novel family C G-protein-coupled receptor. Gene 2004; 335: 37-46.
26. Pi M, Chen L, Huang MZ, Zhu W, Ringhofer B, Luo J, Christenson L, Li B, Zhang J, Jackson PD, Faber P, Brunden KR, Harrington JJ, Quarles LD,. GPRC6A null mice exhibit osteopenia, feminization and metabolic syndrome. PLoS ONE 2008; 3 (12): e3858.
27. Nguyen HH, Takata R, Akamatsu S, Shigemizu D, Tsunoda T, Furihata M, Takahashi A, Kubo M, Kamatani N, Ogawa O, Fujioka T, Nakamura Y, Nakagawa H,. IRX4 at 5p15 suppresses prostate cancer growth through the interaction with vitamin D receptor, conferring prostate cancer susceptibility. Hum Mol Genet 2012; 21 (9): 2076-2085.